ETFs with CELG as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|7.17%||iShares NASDAQ Biotechnology Index Fund (IBB)||+46.33 (34.33%)|
|5.39%||First Trust Amex Biotechnology Index Fund (FBT)||+14.07 (31.13%)|
|4.12%||Columbia Select Large Cap Growth ETF (RWG)||+5.98 (20.54%)|
|3.34%||First Trust Mega Cap Alphadex Fund (FMK)||+3.58 (19.02%)|
|3.27%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+15.12 (17.55%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Celgene Corporation (collectively with its subsidiaries, "we," "our," "us," "Celgene" or the "Company") is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated to innovative research and development designed to bring new therapies to market and are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Celgene was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID®, VIDAZA®, ABRAXANE®, THALOMID® (inclusive of Thalidomide Celgene®), and ISTODAX®. POMALYST® was approved by the U.S. ... More ...